Category - Developments

Developments

InflaRx reports new data for izicopan in liver microsomes

InflaRx (NASDAQ: IFRX) has announced new preclinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Izicopan is an investigational, orally administered, small molecule...

May 4, 2026

Developments

Can-Fite reports positive data from study of namodenoson in pancreatic cancer

Can-Fite Biopharma (NYSE American: CANF; TASE: CANF) has announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer. According to Can-Fite, the data from the...

April 30, 2026

Developments

Oncotelic moving closer to commercial launch of AI-enabled robotics

Oncotelic Therapeutics (OTCQB: OTLC) has announced an update on the advancement of its proprietary AI platform and robotic integration toward commercialization, following the integration of approximately 28 million...

April 30, 2026

Developments

USPTO issues NoA to Nuwellis for catheter technology

Nuwellis (NASDAQ: NUWE) has announced that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance (NoA) for a new patent covering its novel dual-lumen midline catheter technology designed for use...

April 28, 2026

Developments

VivoSim intestinal model combined with AI predicts drug-induced diarrhea without animal testing

VivoSim Labs (NASDAQ: VIVS) has announced the availability of an AI prediction tool leveraging its NAMkind intestinal models to accurately predict the potential of a drug to cause diarrhea in patients, eliminating...

April 28, 2026

Developments

Alto launches Phase 2b trial of ALTO-207 in TRD

Alto Neuroscience (NYSE: ANRO) has initiated its Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study...

April 27, 2026

Developments

FDA grants Immutep ODD for efti in STS

Immutep (NASDAQ: IMMP) has announced that the FDA has granted orphan drug designation (ODD) for eftilagimod alfa (efti) for the treatment of soft tissue sarcoma (STS), a rare cancer with significant unmet medical need...

April 27, 2026

Developments

Clearmind reports positive topline results from CMND-100 trial in AUD

Clearmind Medicine (NASDAQ: CMND) has announced that CMND-100, the company’s proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of alcohol use disorder (AUD), has met the primary endpoint in...

April 27, 2026

Developments

Senseonics launches 365-day implantable CGM for T1/T2 diabetes in Europe

Senseonics Holdings (NASDAQ: SENS) has announced the European launch of the world’s first and only one-year implantable continuous glucose monitoring (CGM) system—Eversense 365—now available to patients with Type 1 and...

April 27, 2026

Developments

Meta-analysis of 17 studies shows no clinically meaningful benefit from anti-amyloid Alzheimer’s drugs

According to the authors of a new Cochrane systemic review which examined data from 17 clinical trials with a total of 20,342 participants, the effect of amyloid‐beta‐targeting monoclonal antibodies on cognitive...

April 16, 2026

Category - Developments

Subscribe